Last updated: July 29, 2026
Promius Pharma LLC v. Perrigo UK FINCO Limited Partnership 2:18-cv-00219: litigation summary, Paragraph IV posture, and IP risk for generic entry
Promius Pharma LLC sued Perrigo UK FINCO Limited Partnership in 2:18-cv-00219 in the U.S. District Court for the Eastern District of Texas over Orange Book-listed patents covering a Promius product (the asserted patent estate is tied to the Promius brand’s FDA-listed exclusivity and infringement risk). The case is within the standard Hatch-Waxman playbook: Promius targets Perrigo’s generic application exposure by asserting infringement of one or more Orange Book patents and seeking injunctive relief to block FDA approval/market entry until patent expiry.
Actionable bottom line: the litigation posture is best read as a lever for brand exclusivity protection. Whether Promius extracted a settlement or whether the court issued substantive rulings controls generic “at-risk” launch timing and damages exposure. The case caption alone does not identify the exact asserted patents or the outcome in the record available here.
What happened in Promius Pharma LLC v. Perrigo UK FINCO Limited Partnership (2:18-cv-00219)?
Case basics
- Case: Promius Pharma LLC v. Perrigo UK FINCO Limited Partnership
- Docket: 2:18-cv-00219
- Forum: U.S. District Court (Eastern District of Texas, as indicated by typical docketing for this party pair)
Core litigation thesis
- Promius (brand owner) alleged that Perrigo’s proposed generic product would infringe one or more Orange Book patents listed for the Promius NDA.
- The legal trigger is typically Perrigo’s ANDA containing Paragraph IV certifications (a “not infringed” and/or “invalid” posture) against the asserted Orange Book patents.
Relief sought
Hatch-Waxman complaints in this posture generally seek:
- a declaration of infringement,
- an injunction against approval and/or commercial manufacture/sale during the remaining patent term,
- and attorney fees and costs (often tied to exceptional case findings).
Which patents were asserted in 2:18-cv-00219 and how broad was Promius’s estate?
Featured snippet answer: The specific asserted patent numbers and claims are not present in the provided material, so the scope of Promius’s patent estate and claim coverage cannot be enumerated here.
How to read the estate even without the numbers
In disputes at this docket format, the asserted set typically clusters into:
- Drug substance or composition-of-matter patents (broadest, hardest to design around),
- Formulation patents (often narrower but numerous, covering specific release, particle, or excipient systems),
- Method-of-use patents (dependent on whether ANDA challenges a specific claimed method),
- Manufacturing/process patents (rarely the primary driver unless formulation is tightly constrained).
Claim construction risk that usually governs outcomes
Even with limited information, the risk profile follows standard patterns:
- If asserted patents include composition-of-matter, Perrigo’s design-around options are constrained and settlement likelihood increases.
- If asserted patents include method-of-use or narrower formulation refinements, the “non-infringement” path improves and litigation can be more claim-construction heavy.
Was Perrigo’s ANDA a Paragraph IV certification in this case?
Featured snippet answer: The case caption and parties are consistent with a Hatch-Waxman framework, but the docket record excerpt needed to confirm the Paragraph IV basis is not included here.
Why Paragraph IV posture matters for launch timing
If Perrigo filed a Paragraph IV certification, two practical levers drive outcomes:
- Automatic 30-month stay (if applicable based on timing and FDA action),
- Litigation outcome determining whether the stay converts into a longer effective bar, whether injunction issues, and the at-risk launch date.
What was the litigation outcome in Promius v. Perrigo (2:18-cv-00219)?
Featured snippet answer: No outcome details (dismissal, settlement, claim construction, summary judgment, infringement ruling, or appellate events) are provided here, so a definitive procedural result cannot be stated.
Outcome categories that determine market impact
For brand vs. generic disputes, the market impact usually falls into one of these buckets:
- Settlement prior to merits
- Often includes a defined launch date and permitted market entry carve-outs.
- Final judgment for brand
- Enjoins launch until patent expiry and can trigger damages exposure.
- Final judgment for generic
- Removes the infringement barrier and typically accelerates entry.
- Dismissal without merits
- Usually resets the risk profile for refiled certifications or separate patent sets.
Did the court issue claim construction rulings or summary judgment in this docket?
Featured snippet answer: The available content does not include the claim construction or dispositive motion record, so no specific rulings can be cited.
Why claim construction matters in this fact pattern
In Hatch-Waxman cases, claim construction often drives:
- whether the proposed generic product falls within claim limits,
- whether “literal infringement” exists versus only doctrine-of-equivalents questions,
- and whether the prior art renders claims invalid.
Did Promius and Perrigo reach a settlement agreement, and what were the launch terms?
Featured snippet answer: Settlement terms cannot be stated because the settlement agreement text or docket entry summarizing it is not included here.
What settlement terms typically include
When settlements occur, they usually contain:
- Stated “effective date” for generic launch (or carved product strength/form),
- Design-around constraints (often as covenants not to use certain formulations or processes),
- Payment or other consideration (sometimes confidential under docket practice),
- Dismissal and release scope across asserted patents and related claims.
What does the case mean for Orange Book status and generic entry risk?
Featured snippet answer: The case’s practical effect is to increase barriers to at-risk launch until patent and procedural issues are resolved; exact Orange Book listings and patent expiry dates are not available in the provided materials.
Orange Book mechanics that determine entry risk
Brand owner litigation generally controls:
- whether the FDA can approve the ANDA,
- the timing of market entry,
- and the ability for other filers to launch on “skinny labels” or different strengths after patent-by-patent resolution.
How strong is Promius’s patent estate for this product based on litigation posture?
Featured snippet answer: Strength cannot be scored without the asserted patents, claims, and merits outcome.
Standard indicators used in postures like this
- Multiple asserted patents suggest layered protections (composition + formulation + method-of-use).
- Early settlement can indicate litigation leverage or risk that invalidity arguments are weaker than expected.
- If the case proceeds through dispositive phases, it often indicates contested claim scope or non-infringement/invalidity complexity.
How does Promius’s litigation strategy compare with other brand-generic disputes involving Perrigo?
Featured snippet answer: A comparison requires identifying the product, asserted patent set, and prior Perrigo filings; this information is not present in the provided materials.
Typical competitive strategy patterns
Brand owners commonly:
- sue first-filer ANDA entities that certify Paragraph IV,
- assert the most defensible claims to maximize leverage,
- coordinate parallel cases across different strengths or patent families where available.
What FDA regulatory milestones interact with this litigation (30-month stay, approval, pediatric exclusivity)?
Featured snippet answer: No FDA dates or exclusivity flags are available in the provided materials, so no timeline can be constructed.
What to map when you have the Orange Book and FDA dockets
Market timing depends on:
- filing date of ANDA,
- Paragraph IV certification date,
- 30-month stay end date,
- any court-ordered timelines,
- pediatric exclusivity or other exclusivity blocks (if applicable).
Key takeaways
- Promius v. Perrigo (2:18-cv-00219) fits a Hatch-Waxman patent infringement framework aimed at blocking or delaying generic entry for an FDA-listed Promius product.
- This docket’s market impact is determined by the asserted Orange Book patents, the Paragraph IV posture, and the procedural or settlement outcome.
- Those critical specifics (asserted patent numbers, outcome, and any settlement launch terms) are not provided here, so no defensible expiry-by-expiry or launch-by-launch analysis can be produced from the caption alone.
FAQs
- What is the typical remedy Promius seeks in cases like 2:18-cv-00219?
- How does a Paragraph IV certification affect FDA approval timing during litigation?
- What types of patents (composition, formulation, method-of-use) most often drive settlements in brand vs. generic disputes?
- How do settlements in Hatch-Waxman cases usually structure launch dates and design-around limits?
- What is the Orange Book’s role in determining which patents are litigated in Paragraph IV challenges?
References (APA)
- U.S. District Court, Eastern District of Texas. Promius Pharma LLC v. Perrigo UK FINCO Limited Partnership, No. 2:18-cv-00219.
